|
|
<section data-role="paragraph" data-color="rgb(182, 228, 253)" data-custom="rgb(182, 228, 253)"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section><p><p><img src="image/20201014/86b79d371e9862b01189f0252a03b2cd_1.png" /></p></p></section><section><section><span><strong></strong></span></section><p><span>医疗器械媒体报道先锋</span></p><p><span>分享专业医疗器械知识</span></p></section><section><section><section>关注</section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section><p><strong><span>来源：中国循环杂志</span></strong></p><p><br /></p><p><span>近些年来，经皮冠状动脉介入术治疗（</span><span>PCI</span><span>）在中国发展较快，支架市场也快速膨胀。而且，随着心血管病的流行，以及老龄化进程，心脏产业支架的“天花板”会更高。</span></p><p><span> </span></p><p><span><strong><span>PCI</span></strong><strong><span>发展迅速但提升空间较大</span></strong></span></p><p><span> </span></p><p><span>据第</span><span>21</span><span>届全国介入心脏病学论坛所公布，</span><span>2017</span><span>年中国大陆地区</span><span>PCI</span><span>次数达到</span><span><span> </span>753142</span><span>次，同比增加</span><span>13%</span><span>左右。</span></p><p><span> </span></p><p><span>按每台</span><span><span> </span>PCI<span> </span></span><span>手术平均使用</span><span><span> </span>1.47</span><span>个心脏支架测算，</span><span>2017</span><span>年中国使用了</span><span>110</span><span>余万枚支架。如果按平均每个支架</span><span>20 mm</span><span>计算，这些支架连起来约</span><span>22</span><span>公里。</span></p><p><span> </span></p><p><p><img src="image/20201014/2e2cd54ac1ef59fbbada9585427dc287_2.png" /></p></p><p><span><span>图</span><span>1 2009~2017</span><span>年中国大陆</span><span>PCI</span><span>手术量及平均心脏支架植入量</span></span><br /></p><p><span> </span></p><p><span>但这</span><span>22</span><span>公里的支架还铺得不够长，平均每</span><span>100</span><span>万人有</span><span>532</span><span>例患者进行</span><span><span> </span>PCI<span> </span></span><span>治疗，而美国每</span><span>100</span><span>万人中有</span><span>3135</span><span>例患者接受</span><span>PCI</span><span>治疗，日本约为</span><span><span> </span>2047<span> </span></span><span>例。</span></p><p><span> </span></p><p><span>鉴于各国心血管病流行病学数据相近，估计中国</span><span>PCI</span><span>手术例数至少有</span><span>3</span><span>倍成长空间，未来心脏支架置入量也将与</span><span>PCI</span><span>手术保持同步增长，估计未来复合增速将维持在</span><span><span> </span>15%</span><span>，也有至少</span><span><span> </span>3<span> </span></span><span>倍的成长空间。</span></p><p><span> </span></p><p><span><strong><span>心脏支架市场前景广阔：乐普、微创、吉威盘踞中国市场前三名</span></strong></span></p><p><span> </span></p><p><span>就全球冠脉支架市场来看，规模估计在</span><span>70</span><span>亿美元左右，增速</span><span>6%</span><span>左右，其中美国和东亚合计占比</span><span>70%</span><span>，此外，中国、巴西、印度等发展中国家<span>市场规模增速呈现快于全球增速的态势，冠脉支架市场规模增速普遍高于</span></span><span>10%</span><span>。</span></p><p><span> </span></p><p><span>就国内来看，假设每个支架终端价格</span><span>8000~9000</span><span>元来计算，国内冠脉支架终端市场规模在</span><span>88~99</span><span>亿元左右。</span></p><p><span> </span></p><p><span>而且，心血管疾病的流行和老龄化进程，还将进一步推动支架产业。</span></p><p><span> </span></p><p><span>从支架技术上看，虽然雅培的可降解支架退市，但全球来看可降解支架研发势头不减，技术的更新换代仍然是支架行业的主题和销售增长驱动力。</span></p><p><span> </span></p><p><span>从</span><span>2017</span><span>年市场份额来看，全球市场上，雅培、波士顿科学和美敦力三家盘踞三甲，市占率分别为</span><span><span> </span>28%</span><span>、</span><span>26%</span><span>、</span><span>23%</span><span>；国内心脏支架行业约</span><span><span> </span>80%</span><span>的市场份额已被国产品牌占领。</span></p><p><span> </span></p><p><span>中国市场市占率排名前三的企业分别是乐普医疗（</span><span>24%</span><span>）、微创医疗（</span><span>23%</span><span>）和吉威医疗（</span><span>20%</span><span>，柏盛国际的全资子公司），</span><span><span> </span>3<span> </span></span><span>家国产心脏支架企业的合计市占率已经达到</span><span><span> </span>67%</span><span>，基本完成了进口替代，未来的趋势是进一步抢占进口企业和其他国产小企业的市场份额。</span></p><p><span> </span></p><p><p><img src="image/20201014/30d13b96532f3487dd730435f2296c2d_3.png" /></p></p><p><span><span>图</span><span>2 </span><span>中国大陆心脏支架植入量市场格局</span></span></p><p><span> </span></p><p><span><strong><span>参考：</span></strong></span></p><p><span><span>[1] </span><span>智研咨询发布的《</span><span>2018-2024</span><span>年中国冠脉支架行业市场发展模式调研及投资趋势分析研究报告》</span></span></p><p><span><span>[2] </span><span>中国产业信息网</span></span></p><p><span> </span></p><section data-id="1658"><section><section><section data-id="1658"><section><section><section data-id="1658"><section><section><section data-id="1658"><section><section><p><span><strong>相关阅读</strong></span></p></section><p><p><img src="image/20201014/ec237188ae1e9c03eb4d9814f31b18ab_4.gif" /></p></p><p><span>【流言】拒绝可怕的心脏支架！</span><br /></p><p><br /></p><p><span>【流言终结者】心脏支架是定时炸弹，还是谣言炸弹？</span><br /></p><p><br /></p><p><span>科普动画|MRI、CT、PET分别是怎么扫描图像的？</span><br /></p><p><br /></p><p><span>【进化】替代移植，人工心脏还要走多远？</span><br /></p></section></section></section></section></section></section></section></section></section></section></section><p><br /></p><p><p><img src="image/20201014/225eae26a91575de7508aebe3e999278_5.jpg" /></p></p>
|
|
发表于 2020-10-14 15:05:39